Cargando…

Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years

OBJECTIVE: The present study was designed to better characterize the clinicopathological features and prognosis in patients aged ≥65 years with pulmonary large cell neuroendocrine carcinoma (LCNEC). METHODS: Eligible patients with pulmonary LCNEC were retrieved from the Surveillance, Epidemiology, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Ling, Zhao, Ling, Wang, Min, Zhang, Xu he, Yang, Zhu-chun, Liu, Yun-peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532618/
https://www.ncbi.nlm.nih.gov/pubmed/31149394
http://dx.doi.org/10.7717/peerj.6824
_version_ 1783421056496697344
author Cao, Ling
Zhao, Ling
Wang, Min
Zhang, Xu he
Yang, Zhu-chun
Liu, Yun-peng
author_facet Cao, Ling
Zhao, Ling
Wang, Min
Zhang, Xu he
Yang, Zhu-chun
Liu, Yun-peng
author_sort Cao, Ling
collection PubMed
description OBJECTIVE: The present study was designed to better characterize the clinicopathological features and prognosis in patients aged ≥65 years with pulmonary large cell neuroendocrine carcinoma (LCNEC). METHODS: Eligible patients with pulmonary LCNEC were retrieved from the Surveillance, Epidemiology, and End Results database between January 2004 and December 2013. The primary endpoints included cancer-specific survival (CSS) and overall survival (OS). RESULTS: Data of 1,619 eligible patients with pulmonary LCNEC were collected. These patients were subsequently categorized into two groups: 890 patients in the older group (age ≥65 years), and 729 in the younger group (age <65 years). More patients were of white ethnicity, stage I, married, and with tumor size <5 cm in the older group in comparison to the younger group. However, there were a significantly lower proportion of patients undergoing surgery, chemotherapy, and radiotherapy in the older group. The 5-year CSS rates of the younger group and older group were 23.94% and 17.94% (P = 0.00031), respectively, and the 5-year OS rates were 20.51% and 13.47% (P < 0.0001), respectively. Multivariate analyses indicated that older age (CSS: HR 1.20, 95% CI [1.07–1.36], P = 0.0024; OS: HR 1.26, 95% CI [1.12–1.41], P < 0.0001) was an independent risk factor for poor prognosis. The mortality risk of the elderly increased in almost every subgroup, especially in OS. Finally, significant predictors for better OS and CSS in patients over age 65 included tumor size <5 cm, lower stage, and receiving surgery, chemotherapy, or radiotherapy. CONCLUSION: The prognosis of patients aged ≥65 years with pulmonary LCNEC was worse than that of younger patients. However, active and effective therapy could significantly improve the survival of older patients with pulmonary LCNEC.
format Online
Article
Text
id pubmed-6532618
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-65326182019-05-30 Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years Cao, Ling Zhao, Ling Wang, Min Zhang, Xu he Yang, Zhu-chun Liu, Yun-peng PeerJ Diabetes and Endocrinology OBJECTIVE: The present study was designed to better characterize the clinicopathological features and prognosis in patients aged ≥65 years with pulmonary large cell neuroendocrine carcinoma (LCNEC). METHODS: Eligible patients with pulmonary LCNEC were retrieved from the Surveillance, Epidemiology, and End Results database between January 2004 and December 2013. The primary endpoints included cancer-specific survival (CSS) and overall survival (OS). RESULTS: Data of 1,619 eligible patients with pulmonary LCNEC were collected. These patients were subsequently categorized into two groups: 890 patients in the older group (age ≥65 years), and 729 in the younger group (age <65 years). More patients were of white ethnicity, stage I, married, and with tumor size <5 cm in the older group in comparison to the younger group. However, there were a significantly lower proportion of patients undergoing surgery, chemotherapy, and radiotherapy in the older group. The 5-year CSS rates of the younger group and older group were 23.94% and 17.94% (P = 0.00031), respectively, and the 5-year OS rates were 20.51% and 13.47% (P < 0.0001), respectively. Multivariate analyses indicated that older age (CSS: HR 1.20, 95% CI [1.07–1.36], P = 0.0024; OS: HR 1.26, 95% CI [1.12–1.41], P < 0.0001) was an independent risk factor for poor prognosis. The mortality risk of the elderly increased in almost every subgroup, especially in OS. Finally, significant predictors for better OS and CSS in patients over age 65 included tumor size <5 cm, lower stage, and receiving surgery, chemotherapy, or radiotherapy. CONCLUSION: The prognosis of patients aged ≥65 years with pulmonary LCNEC was worse than that of younger patients. However, active and effective therapy could significantly improve the survival of older patients with pulmonary LCNEC. PeerJ Inc. 2019-05-20 /pmc/articles/PMC6532618/ /pubmed/31149394 http://dx.doi.org/10.7717/peerj.6824 Text en © 2019 Cao et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Diabetes and Endocrinology
Cao, Ling
Zhao, Ling
Wang, Min
Zhang, Xu he
Yang, Zhu-chun
Liu, Yun-peng
Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years
title Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years
title_full Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years
title_fullStr Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years
title_full_unstemmed Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years
title_short Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years
title_sort clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years
topic Diabetes and Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532618/
https://www.ncbi.nlm.nih.gov/pubmed/31149394
http://dx.doi.org/10.7717/peerj.6824
work_keys_str_mv AT caoling clinicopathologicalcharacteristicsandprognosisofpulmonarylargecellneuroendocrinecarcinomaaged65years
AT zhaoling clinicopathologicalcharacteristicsandprognosisofpulmonarylargecellneuroendocrinecarcinomaaged65years
AT wangmin clinicopathologicalcharacteristicsandprognosisofpulmonarylargecellneuroendocrinecarcinomaaged65years
AT zhangxuhe clinicopathologicalcharacteristicsandprognosisofpulmonarylargecellneuroendocrinecarcinomaaged65years
AT yangzhuchun clinicopathologicalcharacteristicsandprognosisofpulmonarylargecellneuroendocrinecarcinomaaged65years
AT liuyunpeng clinicopathologicalcharacteristicsandprognosisofpulmonarylargecellneuroendocrinecarcinomaaged65years